secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0001628280-24-043761
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive presents Anaphylm data showing consistent PK/PD regardless of film movement
--------------------------------------------------------------------------------

- 87.5% of subjects had no film movement; 12.5% showed movement with no significant PK/PD impact.
- Geometric mean Cmax: 351.14 pg/mL (movement) vs 490.27 pg/mL (no movement); p=0.49.
- Median Tmax was 12 minutes for both groups; comparable to epinephrine injection.
- Data supports Anaphylm as a potential needle-free epinephrine option for anaphylaxis if FDA-approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024043761/0001628280-24-043761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024043761/aqst-20241025.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-043761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer